Role of cholesterol in cardiovascular dysfunction

Canadian Journal of Cardiology

Volumn 20, Issue 3, 2004, Pages 333-346

  Saini, Harjot K ^a,b   Arneja, Amarjit S ^a,b   Dhalla, Naranjan S ^a,b  

^a ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Atherosclerosis; Endothelium; Heart dysfunction; Hypercholesterolemia; Low density lipoproteins; Oxidized cholesterol

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (MAGNESIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMLODIPINE; ANGIOTENSIN; APOLIPOPROTEIN E; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CARRIER PROTEIN; CATION TRANSPORT PROTEIN; CHOLESTEROL; COLESTYRAMINE; CONCANAVALIN A; ENDOTHELIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; NORADRENALIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXYSTEROL; PHENYLEPHRINE; PHOSPHOLIPID; POTASSIUM ION; PRAVASTATIN; QUINAPRIL; REACTIVE OXYGEN METABOLITE; SEROTONIN; SODIUM CALCIUM EXCHANGE PROTEIN; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART CONDUCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE EXCITABILITY; HEART MUSCLE FIBER MEMBRANE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MEMBRANE BINDING; MEMBRANE FLUIDITY; MEMBRANE STRUCTURE; MUSCLE DISEASE; NONHUMAN; OXIDATION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; CA(2+) MG(2+)-ATPASE; CALCIUM-TRANSPORTING ATPASES; CHOLESTEROL; ENDOTHELIUM, VASCULAR; HEART DISEASES; HUMANS; MEMBRANE LIPIDS; NA(+)-K(+)-EXCHANGING ATPASE; OXIDATION-REDUCTION;

EID: 1842787963     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (221)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
2. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis 1981;40:1-52.
3. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
4. Kannel WB, Wilson PW. An update on coronary risk factors. Med Clin North Am 1995;79:951-71.
5. Ravnskov U. Is atherosclerosis caused by high cholesterol? QJM 2002;95:397-403.
6. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
7. Fruchart JC, Duriez P. High density lipoproteins and coronary heart disease. Future prospects in gene therapy. Biochimie 1998;80:167-72.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
9. Sacks FM, Rouleau JL, Moye LA, et al. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol 1995;75:621-3.
10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
11. Lange Y, Swaisgood MH, Ramos BV, Steck TL. Plasma membranes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts. J Biol Chem 1989;264:3786-93.
12. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000;16:459-81.
13. Presti FT. The role of cholesterol in regulating membrane fluidity. In: Gordon LM, ed. Membrane Fluidity in Biology. New York: Academic Press, 1985:97-146.
14. Skipsi VP. Lipid composition of lipoproteins in normal and diseased states. In: Neilson GJ, ed. Blood, Lipids and Lipoproteins: Quantitation, Composition and Metabolism. New York: Wiley-Interscience, 1972:159-71.
15. Jain MK. Role of cholesterol in biomembranes and related systems. Curr Top Membr Transp 1975;5:1-57.
16. Quinn PJ, Chapman D. The dynamics of membrane structure. CRC Crit Rev Biochem 1980;8:1-117.
17. Yeagle PL. Lipid regulation of cell membrane structure and function. FASEB J 1989;3:1833-42.
18. Bastiaanse EM, Hold KM, Van der Laarse A. The effect of membrane cholesterol content on ion transport processes in plasma membranes. Cardiovasc Res 1997;33:272-83.
19. Cooper RA, Arner EC, Wiley JS, Shattil SJ. Modification of red cell membrane structure by cholesterol-rich lipid dispersions. A model for the primary spur cell defect. J Clin Invest 1975;55:115-26.
20. Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane b2 by platelets in vitro. N Engl J Med 1980;302:6-10.
21. Moghadasian MH, Frohlich JJ, McManus BM. Advances in experimental dyslipidemia and atherosclerosis. Lab Invest 2001;81:1173-83.
22. Mcelhaney RN, de Gier J, Neut-Kok EC. The effect of alterations in fatty acid composition and cholesterol content on the nonelectrolyte permeability of Acholeplasma laidlawii B cells and derived liposomes. Biochim Biophys Acta 1973;298:500-12.
23. Grunze M, Deuticke B. Changes of membrane permeability due to extensive cholesterol depletion in mammalian erythrocytes. Biochim Biophys Acta 1974;356:125-30.
24. 2+-ATPase activity of sarcoplasmic reticulum by membrane cholesterol. The effect of enzyme coupling. Biochim Biophys Acta 1981;641:265-9.
25. Schmidt U, Hajjar RJ, Helm PA, et al. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol 1998;30:1929-37.
26. Pfeiffer C, Flemming B, Gunther J, et al. Changes in the excitation contraction coupling in the myocardium of rabbits fed a cholesterol-containing diet. Acta Biol Med Ger 1978;37:1037-47.
27. Hill WG, Zeidel ML. Reconstituting the barrier properties of a water-tight epithelial membrane by design of leaflet-specific liposomes. J Biol Chem 2000;275:30176-85.
28. + permeability and membrane lipid composition in rabbit myocardium after cholesterol rich diet. Experientia 1984;40:812-5.
29. Glitsch HG, Reuter H, Scholz H. The effect of the internal sodium concentration on calcium fluxes in isolated guinea-pig auricles. J Physiol 1970;209:25-43.
30. Strickberger SA, Russek LN, Phair RD. Evidence for increased aortic plasma membrane calcium transport caused by experimental atherosclerosis in rabbits. Circ Res 1988;62:75-80.
31. Bastiaanse EM, Atsma DE, Kuijpers MM, Van der LA. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem. Biophys 1994;58-63.
32. Hoshida S, Yamashita N, Kuzuya T, Hori M. Reduction in infarct size by chronic amlodipine treatment in cholesterol-fed rabbits. Atherosclerosis 1998;138:163-70.
33. Alivisatos SG, Papastavrou C, Drouka-Liapati E, et al. Enzymatic and electrophysiological changes of the function of membrane proteins by cholesterol. Biochem Biophys Res Commun 1977;79:677-83.
34. Senges J, Weihe E, Brachmann J, et al. Effects of hypercholesterolaemia without ischemia on some electrophysiological and ultrastructural properties of the rabbit heart. J Mol Cell Cardiol 1981;13:253-64.
35. Lee RJ, Zaidi IH, Baky SH. Pathophysiology of the atherosclerotic rabbit. Environ Health Perspect 1978;26:225-31.
36. Shah KR, Kolar F, Beamish RE, Dhalla NS. Depression in cardiac contractile force induced by cholesterol. Cardioscience 1990;1:255-9.
37. Szilvassy Z, Ferdinandy P, Szilvassy J, et al. The loss of pacing-induced preconditioning in atherosclerotic rabbits: Role of hypercholesterolaemia. J Mol Cell Cardiol 1995;27:2559-69.
38. Melax H, Leeson TS. Comparative electron microscope studies of the myocardium in adult rats fed on normal and cholesterol diets. J Mol Cell Cardiol 1975;7:195-202.
39. Bastiaanse EM, Jongsma HJ, Van der Laarse A, Takens-Kwak BR. Heptanol-induced decrease in cardiac gap junctional conductance is mediated by a decrease in the fluidity of membranous cholesterol-rich domains. J Membr Biol 1993;136:135-45.
40. Hasin Y, Shimoni Y, Stein O, Stein Y. Effect of cholesterol depletion on the electrical activity of rat heart myocytes in culture. J Mol Cell Cardiol 1980;12:675-83.
41. Renaud JF, Scanu AM, Kazazoglou T, et al. Normal serum and lipoprotein-deficient serum give different expressions of excitability, corresponding to different stages of differentiation, in chicken cardiac cells in culture. Proc Natl Acad Sci USA 1982;79:7768-72.
42. Haigh LS, Leatherman GF, O'Hara DS, et al. Effects of low density lipoproteins and mevinolin on cholesterol content and muscarinic cholinergic responsiveness in cultured chick atrial cells. Regulation of levels of muscarinic receptors and guanine nucleotide regulatory proteins. J Biol Chem 1988;263:15608-18.
43. Bastiaanse EM, Atsma DE, Kuijpers MM, Van der Laarse A. The effect of sarcolemmal cholesterol content on intracellular calcium ion concentration in cultured cardiomyocytes. Arch Biochem Biophys 1994;15:58-63.
44. Rajamannan NM, Sangiorgi G, Springett M, et al. Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis 2001;10:371-4.
45. Wang TD, Chen WJ, Su SS, et al. Increased cardiomyocyte apoptosis following ischemia and reperfusion in diet-induced hypercholesterolemia: Relation to Bcl-2 and Bax proteins and caspase-3 activity. Lipids 2002;37:385-94.
46. Osborne JA, Lento PH, Siegfried MR, et al. Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment. J Clin Invest 1989;83:465-73.
47. Girod WG, Jones SP, Sieber N, et al. Effects of hypercholesterolemia on myocardial ischemia-reperfusion injury in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 1999;19:2776-81.
48. Peterson DW, Griffith DW Jr, Napolitano CA. Decreased myocardial contractility in papillary muscles from atherosclerotic rabbits. Circ Res 1979;45:338-46.
49. David H, Wilfert K, Gunther J, Pfeiffer C, Gross V, Behrisch D. Ultrastructural and functional changes of rabbit myocardium after cholesterol feeding. Acta Biol Med Ger 1978;37:577-91.
50. Blumlein S, Sievers R, Wikman-Coffelt J, Parmley WW. Lack of decreased contractility in hearts from atherosclerotic rabbits. Am Heart J 1983;106:1383-8.
51. Magnuson BA, Schiefer HB, Crichlow EC, et al. Effects of various high-fat diets on myocardial contractility and morphology in rats. Drug Nutr Interact 1988;5:213-26.
52. Hamby RI, Gupta MP, Young MW. Clinical and hemodynamic aspects of single vessel coronary artery disease. Am Heart J 1973;85:458-66.
53. Moraski RE, Russell RO Jr, Smith MK, Rackley CE. Left ventricular function in patients with and without myocardial infarction and one, two or three vessel coronary artery disease. Am J Cardiol 1975;35:1-10.
54. Braun A, Trigatti BL, Post MJ, et al. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002;90:270-6.
55. Yokoyama M, Henry PD. Sensitization of isolated canine coronary arteries to calcium ions after exposure to cholesterol. Circ Res 1979;45:479-86.
56. Rosendorff C, Hoffman JI, Verrier ED, et al. Cholesterol potentiates the coronary artery response to norepinephrine in anesthetized and conscious dogs. Circ Res 1981;48:320-9.
57. Johannsen UJ, Mark AL, Marcus ML, Armstrong ML. Effects of dietary hypercholesterolemia on coronary vasculature responsiveness in vivo. Circulation 1981;64(Suppl IV):267.
58. Takahashi K, Ohyanagi M, Ikeoka K, Iwasaki T. Acetylcholine-induced response of coronary resistance arterioles in cholesterol-fed rabbits. Jpn J Pharmacol 1999;81:156-62.
59. Salt PJ, Iverson LL. Inhibition of the extraneuronal uptake of catecholamine in the isolated rat heart by cholesterol. Nat New Biol 1972;238:91-2.
60. Verbeuren TJ, Simonet S, Herman AG. Diet-induced atherosclerosis inhibits release of noradrenaline from sympathetic nerves in rabbit arteries. Eur J Pharmacol 1994;270:27-34.
61. Shinitzky M, Henkart P. Fluidity of cell membranes - current concepts and trends. Int Rev Cytol 1979;60:121-47.
62. Bretscher MS, Munro S. Cholesterol and the Golgi apparatus. Science 1993;261:1280-1.
63. Pritchard KA Jr, Schwarz SM, Medow MS, Stemerman MB. Effect of low-density lipoprotein on endothelial cell membrane fluidity and mononuclear cell attachment. Am J Physiol 1991;260:C43-9.
64. Papahadjopoulos D, Watkins JC. Phospholipid model membranes. II. Permeability properties of hydrated liquid crystals. Biochim Biophys Acta 1967;135;639-52.
65. Demel RA, Kinsky SC, Kinsky CB, van Deenen LL. Effects of temperature and cholesterol on the glucose permeability of liposomes prepared with natural and synthetic lecithins. Biochim Biophys Acta 1968;150:655-65.
66. de Gier J, Mandersloot JG, van Deenen LL. Lipid composition and permeability of liposomes. Biochim Biophys Acta 1968;150;666-75.
67. Bonting SL, van Breugel PJ, Daemen FJ. Influence of the lipid environment of the properties of rhodopsin in the photoreceptor membrane. Adv Exp Med Biol 1977;83:175-89.
68. Krishnamoorthy I, Krinshnamoorthy G. Probing the link between proton transport and water content in lipid membranes. J Phys Chem 2001;105:1484-8.
69. Papahadjopoulos D, Cowden M, Kimelberg H. Role of cholesterol in membranes. Effects on phospholipid-protein interactions, membrane permeability and enzymatic activity. Biochim Biophys Acta 1973;330:8-26.
70. Chapman D. Some recent studies of lipids, lipid cholesterol and membrane systems. In: Chapman D, Wallch DFA, eds. Biological Membranes, vol 2. London: Academic Press, 1973:91-144.
71. Yeagle, PL. Modulation of membrane function by cholesterol. In: Gold P, Grover S, Roncari DAK, eds. Cholesterol and Coronary Heart Disease. New Jersey: Parthenon Publising Group, 1992:159-74.
72. DePierre JW, Karnoversusky ML. Plasma membranes of mammalian cells: A review of methods for their characterization and isolation. J Cell Biol 1973;56:275-303.
73. +)-ATPase ATP hydrolyzing activity in bovine kidney. Biochemistry 1988;27:6449-52.
74. Schwartz A, Lindenmayer GE, Allen JC. The sodium-potassium adenosine triphosphatase: Pharmacological, physiological and biochemical aspects. Pharmacol Rev 1975;27:3-134.
75. +ATPase activity by cholesterol: Role of hydration. Biochemistry 2000;39:10928-35.
76. +-ATPase. Biochim Biophys Acta 1995;1235:205-12.
77. Roelofsen B. The (non) specificity in the lipid-requirement of calcium- and (sodium plus potassium)-transporting adenosine triphosphatases. Life Sci 1981;29:2235-47.
78. + stimulated, adenosine triphosphatase in rat brain. Nat New Biol 1971;230:148-50.
79. +)-ATPase. Biochim Biophys Acta 1972;266:91-6.
80. +)-stimulated adenosine triphosphatase. J Biol Chem 1974;249:1071-80.
81. 2+. Biochim Biophys Acta 1975;413:143-56.
82. Giraud F, Claret M, Bruckdorfer KR. The effect of membrane-fluidizing agents on sodium-pump activity in erythrocytes. Biochem Soc Trans 1980;8:132.
83. + pump in erythrocytes. Biochim Biophys Acta 1981;647:249-58.
84. Peter JB, Fiehn W, Diazacholesterol myotonia: Accumulation of desmosterol and increased adenosine triphosphatase activity of sarcolemma. Science 1973;179:910-2.
85. Alivisatos SG, Papastavrou C, Drouka-Liapati E, et al. Enzymatic and electrophysiological changes of the function of membrane proteins by cholesterol. Biochem Biophys Res Commun 1977;79:677-83.
86. Gadsby DC, Cranefield PF. Direct measurements of changes in sodium pump current in canine cardiac Purkinje fibers. Proc Natl Acad Sci USA 1979;76:1783-7.
87. 2+ uptake and ATPase activity of fragmented sarcoplasmic reticulum. Biochim Biophys Acta 1972;274:158-70.
88. Bloj B, Galo MG, Morero RD, Farias RN. Heterogeneous effect of dietary cholesterol on acetylcholinesterase and ATPases of rat erythrocytes: Arrhenius plots. J Nutr 1979;109:63-9.
89. Madden TD, Chapman D, Quinn PJ. Cholesterol modulates activity of calcium-dependent ATPase of the sarcoplasmic reticulum. Nature 1979;279:538-41.
90. 2+ ATPase activities of heart sarcolemma, microsomes, and mitochondria. J Biochem (Tokyo) 1977;82:1731-9.
91. 2+-dependent ATPase from rat heart sarcolemma. J Biol Chem 1982;257:14440-5.
92. 2+)-ATPase in enriched sarcolemma from dog heart. Biochim Biophys Acta 1980;598:27-39.
93. 2+-pumping system in dog heart sarcolemma. Nature 1980;283:765-7.
94. Carafoli E, Niggli V, Penniston JT. Purification and reconstruction of the calcium, magnesium ATPase of the erythrocyte membrane. Ann NY Acad Sci 1980;358:159-68.
95. Tada M, Yamamoto T, Tonomura Y. Molecular mechanism of active calcium transport by sarcoplasmic reticulum. Physiol Rev 1978;58:1-79.
96. Dhalla NS, Das PK, Sharma GP. Subcellular basis of cardiac contractile failure. J Mol Cell Cardiol 1978;10:363-85.
97. 2+ATPase. Can J Biochem 1980;58:928-34.
98. 2+-stimulated adenosine triphosphatase and its perturbation by concanavalin A. Biochem J 1980;191:45-51.
99. 2+ ATPase of lymphocyte plasma membranes. Biochem Biophys Res Commun 1980;97:1146-53.
100. Mak WW, Wong JT. Relationship between membrane fluidity and capping of receptors for concanavalin A. Can J Biochem 1980;58:1421-9.
101. Kroes J, Ostwald R, Keith A. Erythrocyte membranes - compression of lipid phases by increased cholesterol content. Biochim Biophys Acta 1972;274:71-4.
102. Leoni S, Luly P, Mangiantini MT, Spagnuolo S. Effect of free fatty acids and cholesterol in vitro on liver plasma membrane-bound enzymes. Experientia 1982;38:102-4.
103. 2+-ATPase from the erythrocyte plasma membrane of the flounder (Platichthys flesus L). Comp Biochem Physiol B 1986;83:467-73.
104. 2+-ATPase by a nonionic detergent. J Biol Chem 1977;252:3551-3.
105. Warren GB, Houslay MD, Metcalfe JC, Birdsall NJ. Cholesterol is excluded from the phospholipid annulus surrounding an active calcium transport protein. Nature 1975;255:684-7.
106. 2+-ATPase activity of sarcoplasmic reticulum by membrane cholesterol. The effect of enzyme coupling. Biochim Biophys Acta 1981;641:265-6.
107. 2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence. Nature 1985;316:696-700.
108. + -ATPase and acetylcholinesterase from rats fed different fat-supplemented diets. Biochim. Biophys Acta 1973;106:67-79.
109. +)-ATPase and acetylcholinesterase from rat erythrocytes. FEBS Lett 1973;38:101-5.
110. 2+)-ATPase from cardiac muscle. Biochim Biophys Acta 1984;773:231-6.
111. Ortega A, Mas-Oliva J. Direct regulatory effect of cholesterol on the calmodulin stimulated calcium pump of cardiac sarcolemma. Biochem Biophys Res Commun 1986;139:868-74.
112. Moffat MP, Dhalla NS. Heart sarcolemmal ATPase and calcium binding activities in rats fed a high cholesterol diet. Can J Cardiol 1985;1:194-200.
113. Kutryk MJ, Pierce GN. Stimulation of sodium-calcium exchange by cholesterol incorporation into isolated cardiac sarcolemmal vesicles. J Biol Chem 1988;263:13167-72.
114. Zhou Q, Jimi S, Smith TL, Kummerow FA. The effect of cholesterol on the accumulation of intracellular calcium. Biochim Biophys Acta 1991;1085:1-6.
115. Zhou Q, Jimi S, Smith TL, Kummerow FA. The effect of 25-hydroxycholesterol on accumulation of intracellular calcium. Cell Calcium 1991;12:467-76.
116. 2+)-ATPase from cardiac muscle sarcolemma. Biochem Int 1990;21:233-41.
117. 2+-ATPase of cardiac microsomes. Biochim Biophys Acta 1996;1283:45-50.
118. + channels and membrane fluidity in vascular smooth muscle cells. Pflugers Arch 1989;415:262-8.
119. + channel-mediated vasodilatation in vivo. Am J Physiol Heart Circ Physiol 2000;279:H1600-8.
120. Chobanian AV, Menzoian JO, Shipman J, et al. Effects of endothelial denudation and cholesterol feeding on in vivo transport of albumin, glucose, and water across rabbit carotid artery. Circ Res 1983;53:805-14.
121. Verlangieri AJ, Cardin BA, Bush M. The interaction of aortic glycosaminoglycans and 3H-inulin endothelial permeability in cholesterol induced rabbit atherogenesis. Res Commun Chem Pathol Pharmacol 1985;47:85-96.
122. Rifkind BM. Diet, plasma cholesterol and coronary heart disease. J Nutr 1986;116:1578-80.
123. Ross R. The pathogenesis of atherosclerosis: An update. N Engl J Med 1986;314:488-500.
124. Yamamoto H, Bossaler C, Cartwright J Jr, Henry PD. Videomicroscopic demonstration of defective cholinergic arteriolar vasodilation in atherosclerotic rabbit. J Clin Invest 1988;81:1752-8.
125. Zeiher AM, Drexler H, Woltschlarger H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary flow regulation in patients with early atherosclerosis. Circulation 1991;84:1984-92.
126. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991;338:1546-50.
127. Lamping KG, Piegors DJ, Benzuly KH, et al. Enhanced coronary vasoconstrictive response to serotonin subsides after removal of dietary cholesterol in atherosclerotic monkeys. Arterioscler Thromb 1994;14:951-7.
128. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-500.
129. Egashira K, Hirooka Y, Kai H, et al. Reduction of serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
130. Gould KL, Martucci JP, Goldberg GI, et al. Short term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89:1530-8.
131. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997;95:324-8.
132. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999;31:51-60.
133. Sun YP, Lu NC, Parmley WW, Hollenbeck CB. Effects of cholesterol diets on vascular function and atherogenesis in rabbits. Proc Soc Exp Biol Med 2000;224:166-71.
134. Laufs U, Fata VL, Plutzky J, Liano JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97;1129-35.
135. Radomski MW, Palmer RM, Moncada S. The antiaggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmcol 1987;92:639-46.
136. Ma XL, Weyrich AS, Lefer DJ, Lefer AM. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 1993;72:403-12.
137. Tsao PS, McEvoy LM, Drexler H, et al. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994;89:2176-82.
138. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-7.
139. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischaemic heart disease. Circ J 2002;66:529-33.
140. Cooke JP, Dzau VJ. Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 1997;48:489-509.
141. Boulanger C. Release of endothelin by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-90.
142. Lerman A. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation 1992;85:1894-8.
143. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 2000;93:65-77.
144. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
145. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension 1991;18:132-41.
146. Kim JA, Brliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Commun 1996;226:862-8.
147. Kubo A, Fukuda N, Soma M, et al. Inhibitory effect of angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996;27:58-63.
148. Yanagiati Y, Rakugi H, Okamura A, et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999;33:335-9.
149. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptors, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996;16:97-105.
150. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997;29;366-73.
151. Imai T, Hirata Y, Emori T, et al. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992;19:753-7.
152. Manacini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94:258-65.
153. Toda T, Leszczynski D, Kummerow F. Angiotoxic effects of dietary 7-ketocholesterol in chick aorta. Paroi Arterielle 1981;7:167-75.
154. Jacobson MS, Price MG, Shamoo AE, Heald FP. Atherogenesis in white carneau pigeons. Effects of low-level cholestane-triol feeding. Atherosclerosis 1985;57:209-17.
155. Imai H, Nakamura H. Short term responses to cholesterol and oxygenated derivatives. Fed Proc 1980;39:772.
156. Peng SK, Taylor CB, Hill JC, Morin RJ. Cholesterol oxidation derivatives and arterial endothelial damage. Atherosclerosis 1985;54:121-33.
157. Boissonneault GA, Hennig B, Ouyang CM. Oxysterols, cholesterol biosynthesis, and vascular endothelial cell monolayer barrier function. Proc Soc Exp Biol Med 1991;196:338-43.
158. Leonarduzzi G, Sevanian A, Sottero B, et al. Up-regulation of the fibrogenic cytokine TGF-beta 1 by oxysterols: A mechanistic link between cholesterol and atherosclerosis. FASEB J 2001;15:1619-21.
159. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease. Ann Intern Med 1971;74:1-12.
160. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983;52:223-61.
161. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
162. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediate uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979:76:333-7.
163. Morel DW, Dicorleto PE, Chisolm GM. Endothelial and smooth muscles after low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984;4:357-64.
164. Steinebrecher UP, Parthasarathy S, Leake DS, et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984;81:3883-7.
165. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells. Circ Res 1994;74:1141-8.
166. Mugge A. The role of reactive oxygen species in atherosclerosis. Z Kardiol 1998;87:851-64.
167. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation 1999;99:2027-33.
168. Usio-Fukai M, Zafari AM, Fukui T, et al. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996:271;23317-21.
169. Zhang H, Schmeisser A, Garlichs CD, et al. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH/NADPH-oxidases. Cardiovasc Res 1999;44:215-22.
170. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995;115:201-15.
171. O'Donnell VB, Freeman BA. Interactions between nitric oxide and lipid oxidation pathways: Implications for vascular disease. Circ Res 2001;88:12-21.
172. Muzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerine treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III mediated superoxide production and vascular NO bioavailability. Circ Res 2000;86:E7-12.
173. Oelze M, Mollnau H, Hoffmann N, et al. Vasodilator-stimulated phophoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signalling and endothelial dysfunction. Circ Res 2000;87:999-1005.
174. Nakashima Y, Raines EW, Plump AS, et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998;18:842-51.
175. Carpers QT, Alexander RW, Lou P, et al. Monocyte chemoattract protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997;30:1397-402.
176. Han KH, Tangirala RK, Green SR, Quehenberger O. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1 mediated chemotaxis in human monocytes: A regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol 1998;18:1983-91.
177. Chisolm GM, Steinberg D. The oxidative modification
178. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995-8.
179. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134-8.
180. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-7.
181. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, Curtiss LK. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 1994;14:47-53.
182. Mietus-Snyder M, Friera A, Glass CK, Pitas RE. Regulation of scavenger receptor expression in smooth muscle cells by protein kinase C. Arterioscler Thromb Vasc Biol 1997;17:969-78.
183. Dayuan L, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:1116-22.
184. Sakurai K, Sawamura T. Stress and vascular responses: Endothelial dysfunction via lectin-like oxidized low density lipoprotein receptor-1: Close relationships with oxidative stress. J Pharmacol Sci 2003;91:182-6.
185. Jovinge S, Ares MP, Kallin B, Nilsson J. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol 1996;16:1573-9.
186. Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 1983;3:215-22.
187. Xu XP, Meisel SR, Ong JM, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999;99:993-8.
188. Carpenter KL, Taylor SE, Ballantine JA, et al. Lipids and oxidised lipids in human atheroma and normal aorta. Biochem Biophys Acta 1993;1167:121-30.
189. Smith LL, Van Lier JE. Sterol metabolism. 9.26-hydroxycholesterol levels in the human aorta. Atherosclerosis 1970;12:1-14.
190. Carpenter KL, Taylor SE, van der Veen C, et al. Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochem Biophys Acta 1995;1256:141-50.
191. Brown AJ, Leong SL, Dean RT, Jessup W. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J Lipid Res 1997;38:1730-45.
192. Hodis HN, Crawford DW, Sevanian A. Cholesterol feeding increases plasma and aortic tissue cholesterol oxide levels in parallel: Further evidence for the role of cholesterol oxidation in atherosclerosis. Atherosclerosis 1991;89:117-26.
193. Staprans I, Pan XM, Rapp JH, Feingold KR. Oxidized cholesterol in the diet accelerates the development of aortic atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1998;18:977-83.
194. Peng SK, Tham P, Taylor CB, Mikkelson B. Cytotoxicity of oxidation derivatives of cholesterol on cultured aortic smooth muscle cells and their effect on cholesterol biosynthesis. Am J Clin Nutt 1979;32:1033-42.
195. Raaphorst GP, Azzam EI, Langlois R, Van Lier JE. Effect of cholesterol alpha and beta epoxides on cell killing and transformation. Biochem Pharmacol 1987;36:2369-72.
196. Lizard G, Lemaire S, Monier S, Gueldry S, Neel D, Gambert P. Induction of apoptosis and of interleukin-1beta secretion by 7-beta-hydroxycholesterol and 7-ketocholesterol: Partial inhibition by Bcl-2 overexpression. FEBS Lett 1997;419:276-80.
197. Liu Y, Hulten LM, Wiklund O. Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol 1997;17:317-23.
198. Kraemer R, Pomerantz KB, Joseph-Silverstein J, Hajjar DP. Induction of basic fibroblast growth factor mRNA and protein synthesis in smooth muscle cells by cholesteryl ester enrichment and 25-hydroxycholesterol. J Biol Chem 1993;268:8040-5.
199. Lemaire S, Lizard G, Monier S, et al. Different patterns of IL-1beta secretion, adhesion molecule expression and apoptosis induction in human endothelial cells treated with 7alpha-, 7beta-hydroxycholesterol, or 7-ketocholesterol. FEBS Lett 1998;440:434-9.
200. Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993;171:223-9.
201. Landis MS, Patel HV, Capone JP. Oxysterol activators of liver X receptor and 9-cis-retinoic acid promote sequential steps in the synthesis and secretion of tumor necrosis factor-alpha from human monocytes. J Biol Chem 2002;277:4713-21.
202. Brown MS, Goldstein JL. Regulation of the activity of the low density lipoprotein receptor in human fibroblasts. Cell 1975;6:307-16.
203. Peng SK, Hu B, Hsiao W, Morin R. Influence of cholesterol oxides on endocytosis of cultured endothelial and smooth muscle cells. Artery 1990;17:84-95.
204. Morin RJ, Peng SK. Effects of cholesterol oxidation derivatives on cholesterol esterifying and cholesteryl ester hydrolytic enzyme activity of cultured rabbit aortic smooth muscle cells. Lipids 1989;24:217-20.
205. Peng SK, Hu B, Peng AY, Morin RJ. Effect of cholesterol oxides on prostacyclin production and platelet adhesion. Artery 1993;20:122-34.
206. Hennig B, Boissonneault GA. Cholestan-3 beta, 5 alpha, 6 beta-triol decreases barrier function of cultured endothelial cell monolayers. Atherosclerosis 1987;68:255-61.
207. Henning B, Kline RP, Siegal MS, Wit AL. Triggered activity in atrial fibres of canine coronary sinus: Role of extracellular potassium accumulation and depletion. J Physiol 1987;383:191-211.
208. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990;85:1260-6.
209. Bruschke AVG, Kramer JR Jr, Bal ET, et al. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times. Am Heart J 1989;117:296-305.
210. Bissett JK, Wyeth RP, Matts JP, Johnson JW. Plasma lipid concentrations and subsequent coronary occlusion after a first myocardial infarction. The POSCH group. Am J Med Sci 1993;305:139-44.
211. Shub C, Vlietstra RE, Smith HC, et al. The unpredictable progression of symptomatic coronary artery disease: A serial clinical-angiographic analysis. Mayo Clin Proc 1981;56:155-60.
212. Krauss RM, Lindgren FT, Williams PT, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet 1987;2:62-6.
213. Louis A, Manousos I, Coletta A, et al. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Eur J Heart Failure 2002;4:111-6.
214. Morris DL, Kritcheversusky SB, Davis CE. Serum carotenoids and coronary heart disease: The Lipid Research Clinics Coronary Primary Prevention and Follow-up Study. J Am Med Assoc 1994;272:1439-41.
215. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
216. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Resuts of the GISSI-Prevenzione trial. Lancet 1999;354:447-55.
217. The Heart Outcomes Prevention Evaluation Study. Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med 1999;342:154-60.
218. Brown M. Do vitamin E and fish oil protect against ischemic heart disease? Lancet 1999;354:441-2.
219. Jialal I, Devaraj S, Huet BA, Traber M. GISSI-Prevenzione trial. Lancet 1999;354:1556-7. (Lett)
220. Thomas SR, Stocker R. Molecular action of vitamin E in lipoprotein oxidation: Implications for atherosclerosis. Free Radic Biol Med 2000;28:1795-805.
221. Salonen RM, Nyyssonen K, Kaikkonen J, et al. Six year effect of combined vitamin C and E supplementation on atherosclerotic progression. The antioxidant supplementation in atherosclerotic prevention (ASAP) study. Circulation 2003;107:947-53.